CKPT: Checkpoint Therapeutics Inc. Market Capitalization-to-Revenue Ratio
Checkpoint Therapeutics (CKPT) maintains a strong R&D center, attracting leading experts through a stock option system. The price/sales multiple reflects the valuation trend, with the indicator holding at 9239.00. The biotech startup is implementing affordable targeted therapy methods. The strategy is based on reducing development costs for cosibelimab, enabling the company to offer effective skin cancer treatment at a competitive price.
Metric breakdowns and analytics for Checkpoint Therapeutics, Inc (CKPT)
- market price and analyst price targets:
- market capitalization information:
- book capitalization indicators:
- debt obligations and liquidity statistics:
Total Debt to Capital Checkpoint Therapeutics|CKPT - Long-Term Debt to Equity|Current Liabilities to Equity Checkpoint Therapeutics Inc|CKPT - Company Debts|Debts to Book Value Checkpoint Therapeutics, Inc|CKPT - Company Long-Term Debts|Short-Term Debt Volume Checkpoint Therapeutics|Immediate Liquidity Ratio checkpointtx.com
- earnings and multiples data:
CKPT - Net Income|Future Net Profit Checkpoint Therapeutics|CKPT - Price to Earnings Ratio|Future Price to Earnings Multiple Checkpoint Therapeutics Inc.|CKPT - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Checkpoint Therapeutics, Inc|CKPT - Operating profit EBITDA|Earnings per share for the trailing year Checkpoint Therapeutics|CKPT - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months checkpointtx.com|CKPT - Earnings per share growth in current year|Expected earnings per share trend next year Checkpoint Therapeutics
- issuer revenue and sales details:
Fundamental company analysis:CKPT - checkpointtx.com
Checkpoint Therapeutics operates within an autonomous drug development cycle, where the demand for medical innovation renders the business resilient to global macroeconomic shocks. By analyzing the price-to-sales trend, an investor assesses the ratio of market capitalization to annual sales volume, which allows for the determination of the asset's overvaluation or the business's growth potential based on current revenue generation rates.
Competing companies
Market Cap to Revenue beigene.com ONC|P/S Multiple HALO (Halozyme)|Market Capitalization-to-Revenue Ratio RVMD|Ascentage - P/S Multiple|Price to Sales CG Oncology Therapeutics|URGN: P/S Multiple|Market Cap to Revenue bicara.com|Price-to-Revenue Ratio Personalis|P/S Multiple Erasca Inc|Price-to-Revenue Ratio Delcath (DCTH)|YMAB: Price-to-Sales Ratio|Price-to-Revenue Ratio Aura Biosciences, Inc. AURA|Candel Therapeutics Inc. (CADL) - Price to Sales|Accuray - P/S Multiple|Price-to-Revenue Coefficient SELLAS Life Sciences SLS|Actuate Therapeutics, Inc (ACTU) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CTOR|Market Cap to Revenue HURA|TARA (protaratx.com) - Market Cap to Sales Volume|Market Cap to Revenue FATE (Fate Therapeutics)|WHWK (aadibio.com) - Market Capitalization-to-Revenue Ratio|TScan Therapeutics, Inc. - Market Cap to Revenue|Market Cap to Sales Volume CSBR (Champions Oncology Inc)|XBiotech USA - P/S Multiple|Market Capitalization-to-Revenue Ratio CVM (CEL-SCI Corporation)|OSTX: P/S Multiple|Price to Sales radiopharmtheranostics.com (RADX)|Price-to-Revenue Ratio Artiva Biotherapeutics Inc.|ANL: Market Capitalization-to-Revenue Ratio|P/S Multiple VERU|P/S Multiple tempesttx.com (TPST)|Price-to-Revenue Ratio Xilio Therapeutics XLO|RENB (Renovaro Biosciences) - Price-to-Sales Ratio|Mural Bio - P/S Multiple|Price to Sales Kairos Pharma Ltd|OKUR (onkuretherapeutics.com) - Market Cap to Revenue|CytoMed Therapeutics Limited (GDTC) - P/S Multiple|Market Cap to Revenue CRIS|APLM (Apollomics Corp) - Market Cap to Sales Volume|P/S Multiple THAR|Price-to-Revenue Coefficient advanbiomed.com|P/S Multiple GNPX (Genprex, Inc.)|CLDI - Market Cap to Revenue|SBFM - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Xenetic Biosciences XBIO|SLRX: P/S Multiple|Market Cap to Revenue Kitov Pharma|Price-to-Revenue Ratio American Oncology Network Inc|P/S Multiple beigene.com|Price-to-Revenue Ratio Elevation Oncology (ELEV)|ICAD: Price-to-Sales Ratio|Ikena Oncology - Market Cap to Revenue|Market Cap to Sales Volume NTBL (Notable Labs Corp)|Viracta - P/S Multiple|morphosys.com (MOR) - Market Cap to Revenue|NAYA: P/S Multiple|Ascentage Pharma Group International (AAPGV) - P/S Multiple
